Rifaximin has a good inhibitory activity against Staphylococcus, Streptococcus, Enterococcus, Escherichia coli, Shigella, Salmonella, Bacillus cereus, Moraxella catarrhalis, Haemophilus influenzae, Haemophilus ducreyi, Bacteroides bivius-disiens, Gardnerella vaginalis, Lactobacillus spp.,Mobiluncus spp.,Neisseria gonorrhoeae, Pseudomonas and Acinetobacter . Rifaximin rarely causes side effects.
Rifaximin (0.1, 1.0 and 10.0 µM) causes significant and concentration-dependent reduction of cell proliferation, cell migration and PCNA expression in the Caco-2 cells vs. untreated cells.
Rifaximin (0.1-10 μM) downregulates Akt/mTOR and p38MAPK/NF-κB pathways through a PXR-dependent mechanism.
Cell Viability Assay
| Cell Line: |
Caco-2 cells |
| Concentration: |
0.1, 1.0 and 10.0 μM |
| Incubation Time: |
48 hours |
| Result: |
Caused a significant and concentration-dependent reduction in cell proliferation.
Reduced the expression of PCNA in a concentration-dependent manner.
|
Western Blot Analysis
| Cell Line: |
Caco-2 cells |
| Concentration: |
0.1, 1.0 and 10.0 μM |
| Incubation Time: |
24 hours |
| Result: |
Reduced Akt, mTOR, p38 MAPK and HIF-1α expression in a concentration-dependent manner.
Inhibited NF-κB nuclear activation and p70S6K.
|